<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urmj</journal-id><journal-title-group><journal-title xml:lang="ru">Уральский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Ural Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-4389</issn><publisher><publisher-name>Ural State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52420/umj.23.3.36</article-id><article-id custom-type="edn" pub-id-type="custom">DPNWPQ</article-id><article-id custom-type="elpub" pub-id-type="custom">urmj-1533</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи | Original articles</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles</subject></subj-group></article-categories><title-group><article-title>Прокоагулянтная готовность у пациентов с артериальной гипертензией и мультифокальным атеросклерозом</article-title><trans-title-group xml:lang="en"><trans-title>Pro‑coagulant Considerations in Patients with Arterial Hypertension and Multifocal Atherosclerosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5219-9216</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Веденская</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Vedenskaya</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Сергеевна Веденская  — кандидат медицинских наук, доцент кафедры факультетской терапии, эндокринологии, аллергологии и иммунологии</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>Svetlana S. Vedenskaya — Candidate of Sciences (Medicine), Associate Professor of the Department of Faculty Therapy, Endocrinology, Allergology and Immunology</p><p>Ekaterinburg</p></bio><email xlink:type="simple">ssveden@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0705-6651</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смоленская</surname><given-names>О. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Smolenskaya</surname><given-names>O. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Георгиевна Смоленская — доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии, эндокринологии, аллергологии и иммунологии</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>Olga G. Smolenskaya — Doctor of Sciences (Medicine), Professor, Head of the Department of Faculty Therapy, Endocrinology, Allergology and Immunology</p><p>Ekaterinburg</p></bio><email xlink:type="simple">o.smolenskaya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9397-4063</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грачёв</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Grachev</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вадим Геннадьевич Грачёв — кандидат медицинских наук, доцент кафедры факультетской терапии, эндокринологии, аллергологии и иммунологии</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>Vadim G. Grachev — Candidate of Sciences (Medicine), Associate Professor of the Department of Faculty Therapy, Endocrinology, Allergology and Immunology</p><p>Ekaterinburg</p></bio><email xlink:type="simple">grach_vad@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5063-5571</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Клячина</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Klyachina</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Екатерина Сергеевна Клячина — ассистент кафедры факультетской терапии, эндокринологии, аллергологии и иммунологии</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>Ekaterina S. Klyachina — Assistant of the Department of Faculty Therapy, Endocrinology, Allergology and Immunology</p><p>Ekaterinburg</p></bio><email xlink:type="simple">katrina.s.sharm@mail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-1817-1250</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Широбокова</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shirobokova</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ксения Владимировна Широбокова — заведующий клинико-диагностической лабораторие</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>Ksenia V. Shirobokova — Head of the Clinical Diagnostics Laboratory</p><p>Ekaterinburg</p></bio><email xlink:type="simple">ksenia.kirillova@citilab.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Уральский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Ситилаб-Урал</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sitilab-Ural</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>11</day><month>07</month><year>2024</year></pub-date><volume>23</volume><issue>3</issue><fpage>36</fpage><lpage>45</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Веденская С.С., Смоленская О.Г., Грачёв В.Г., Клячина Е.С., Широбокова К.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Веденская С.С., Смоленская О.Г., Грачёв В.Г., Клячина Е.С., Широбокова К.В.</copyright-holder><copyright-holder xml:lang="en">Vedenskaya S.S., Smolenskaya O.G., Grachev V.G., Klyachina E.S., Shirobokova K.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.umjusmu.ru/jour/article/view/1533">https://www.umjusmu.ru/jour/article/view/1533</self-uri><abstract><p>Цель работы — установить особенности гемостаза и реологии крови у пациентов с артериальной гипертензией (АГ) и мультифокальным атеросклеротическим поражением (МФАП).</p><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включены мужчины и женщины в возрасте 40–70 лет, из них 59 пациентов с контролируемой АГ I–II стадий, имеющие мультифокальное поражение сосудистого русла (1 группа), и 42 пациента с контролируемой АГ III стадии, перенесших ишемический инсульт и имеющих мультифокальное поражение сосудистого русла (2 группа). Для выявления нарушений гемостаза проводили тест на анализаторе «Регистратор тромбодинамики Т-2» (ООО «ГемаКор», Москва, Россия).</p></sec><sec><title>Результаты</title><p>Результаты. Пациенты с АГ и МФА имеют нарушения в системе коагуляционного гемостаза (увеличение средней и начальной скоростей роста сгустка, размера сгустка, а также наличие спонтанных сгустков), что приводит к высокому остаточному риску развития церебральных осложнений, несмотря на снижение АД до целевых цифр и контроль липидного спектра.</p></sec><sec><title>Обсуждение</title><p>Обсуждение. Повышенное артериальное давление у пациентов с МФА приводит к дисфункции эндотелия, что сопровождается активацией путей коагуляции и фибринолиза. Эти изменения приводят к нарушению микроциркуляторного гемостаза в головном мозге, развитию и прогрессированию церебральной ишемии, а в последующем и возникновению инсульта, как первого, так и повторного.</p></sec><sec><title>Заключение</title><p>Заключение. Важным результатом настоящей работы является впервые выявленное изменение коагуляционного звена гемостаза у пациентов 40–70 лет с АГ и МФАП, которое можно рассматривать как дополнительный предиктор развития инсульта.</p></sec></abstract><trans-abstract xml:lang="en"><p>The aim of the work to determine the features of hemostasis and blood rheology in patients with arterial hypertension (HTN) and multifocal atherosclerosis (MFA).</p><sec><title>Materials and methods</title><p>Materials and methods. The study enrolled male and female patients aged from 40 to 70 years, including 59 patients with controlled stage I–II hypertension and multifocal vascular lesions (Group 1) and 42 patients with controlled stage III hypertension, who have suffered an ischemic stroke and have multifocal vascular lesions (Group 2). A test using the Thrombodynamics analyser system T-2 (GemaKor, LLC, Moscow, Russia) was performed to detect the impairment of hemostasis.</p></sec><sec><title>Results</title><p>Results. Patients with HTN and MFA have an impaired coagulation hemostasis system (an increase in the initial and stationary clot growth rate and the size of the clot, as well as the presence of spontaneous clots), which leads to a high residual risk of cerebral complications, despite BP lowering to target figures and control of lipid profile.</p></sec><sec><title>Discussion</title><p>Discussion. Elevated blood pressure in patients with MFA leads to endothelial dysfunction, which is accompanied by activation of coagulation and fibrinolysis pathways. These changes lead to a violation of microcirculatory hemostasis in the brain, the development and progression of cerebral ischemia, and subsequently the occurrence of stroke, both the first and repeated.</p></sec><sec><title>Conclusion</title><p>Conclusion. An important result of this study is the first registered change in the coagulation link of hemostasis in patients with HTN and MFA aged from 40 to 70 years, which can be considered an additional criterion for stroke prediction.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>мультифокальный атеросклероз</kwd><kwd>нарушения в системе гемостаза</kwd><kwd>тромбодинамика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>multifocal atherosclerosis</kwd><kwd>impairment of hemostasis</kwd><kwd>thrombodynamics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165–182. DOI: https://doi.org/10.1001/jama.2016.19043. Erratum in: Incorrect Values and Excluded Units of Measure. JAMA. 2017;317(6):648. DOI: https://doi.org/10.1001/jama.2017.0013.</mixed-citation><mixed-citation xml:lang="en">Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165–182. DOI: https://doi.org/10.1001/jama.2016.19043. Erratum in: Incorrect Values and Excluded Units of Measure. JAMA. 2017;317(6):648. DOI: https://doi.org/10.1001/jama.2017.0013.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, et al. Hypertension management in patients with cardiovascular comorbidities. European Heart Journal. 2023;44(23):2066–2077. DOI: https://doi.org/10.1093/eurheartj/ehac395.</mixed-citation><mixed-citation xml:lang="en">Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, et al. Hypertension management in patients with cardiovascular comorbidities. European Heart Journal. 2023;44(23):2066–2077. DOI: https://doi.org/10.1093/eurheartj/ehac395.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Carey RM, Moran AE, Whelton PK. Treatment of hypertension: A review. JAMA. 2022;328(18):1849–1861. DOI: https://doi.org/10.1001/jama.2022.19590.</mixed-citation><mixed-citation xml:lang="en">Carey RM, Moran AE, Whelton PK. Treatment of hypertension: A review. JAMA. 2022;328(18):1849–1861. DOI: https://doi.org/10.1001/jama.2022.19590.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Poredos P, Jezovnik MK. Preclinical carotid atherosclerosis as an indicator of polyvascular disease: A narrative review. Annals of Translational Medicine. 2021;9(14):1204. DOI: https://doi.org/10.21037/atm-20-5570.</mixed-citation><mixed-citation xml:lang="en">Poredos P, Jezovnik MK. Preclinical carotid atherosclerosis as an indicator of polyvascular disease: A narrative review. Annals of Translational Medicine. 2021;9(14):1204. DOI: https://doi.org/10.21037/atm-20-5570.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sebastian SA, Co EL, Tidd-Johnson A, Chowdhury S, Jain E, Davidson M, et al. Usefulness of carotid ultrasound screening in primary cardiovascular prevention: A systematic review. Current Problems in Cardiology. 2023;49(1 Pt C):102147. DOI: https://doi.org/10.1016/j.cpcardiol.2023.102147.</mixed-citation><mixed-citation xml:lang="en">Sebastian SA, Co EL, Tidd-Johnson A, Chowdhury S, Jain E, Davidson M, et al. Usefulness of carotid ultrasound screening in primary cardiovascular prevention: A systematic review. Current Problems in Cardiology. 2023;49(1 Pt C):102147. DOI: https://doi.org/10.1016/j.cpcardiol.2023.102147.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bockeria LA, Spiridonov AA, Buziashvili YuI, Alekyan BG, Makarenko VN, Pirtskhalaishvili ZK, et al. Cardiac complications in patients with atherosclerotic combined lesions of the brachiocephalic arteries and the abdominal aorta. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2005;6(1):44–53. (In Russ). EDN: https://elibrary.ru/kvqogh.</mixed-citation><mixed-citation xml:lang="en">Bockeria LA, Spiridonov AA, Buziashvili YuI, Alekyan BG, Makarenko VN, Pirtskhalaishvili ZK, et al. Cardiac complications in patients with atherosclerotic combined lesions of the brachiocephalic arteries and the abdominal aorta. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2005;6(1):44–53. (In Russ). EDN: https://elibrary.ru/kvqogh.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al.; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–189. DOI: https://doi.org/10.1001/jama.295.2.180.</mixed-citation><mixed-citation xml:lang="en">Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al.; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–189. DOI: https://doi.org/10.1001/jama.295.2.180.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cimmino G, Muscoli S, De Rosa S, Cesaro A, Perrone MA, Selvaggio S, et al. Pathogenesis of atherosclerosis working group of the Italian Society of Cardiology. Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation. Journal of Cardiovascular Medicine. 2023;24(Suppl 2):e156–e167. DOI: https://doi.org/10.2459/JCM.0000000000001450.</mixed-citation><mixed-citation xml:lang="en">Cimmino G, Muscoli S, De Rosa S, Cesaro A, Perrone MA, Selvaggio S, et al. Pathogenesis of atherosclerosis working group of the Italian Society of Cardiology. Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation. Journal of Cardiovascular Medicine. 2023;24(Suppl 2):e156–e167. DOI: https://doi.org/10.2459/JCM.0000000000001450.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Di Costanzo A, Indolfi C, Sorrentino S, Esposito G, Spaccarotella CAM. The effects of statins, ezetimibe, PCSK9-inhibitors, inclisiran, and icosapent ethyl on platelet function. International Journal of Molecular Sciences. 2023;24(14):11739. DOI: https://doi.org/10.3390/ijms241411739.</mixed-citation><mixed-citation xml:lang="en">Di Costanzo A, Indolfi C, Sorrentino S, Esposito G, Spaccarotella CAM. The effects of statins, ezetimibe, PCSK9-inhibitors, inclisiran, and icosapent ethyl on platelet function. International Journal of Molecular Sciences. 2023;24(14):11739. DOI: https://doi.org/10.3390/ijms241411739.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Goli RR, Contractor MM, Nathan A, Tuteja S, Kobayashi T, Giri J. Antiplatelet therapy for secondary prevention of vascular disease complications. Current Atherosclerosis Reports. 2017;19(12):56. DOI: https://doi.org/10.1007/s11883-017-0698-2.</mixed-citation><mixed-citation xml:lang="en">Goli RR, Contractor MM, Nathan A, Tuteja S, Kobayashi T, Giri J. Antiplatelet therapy for secondary prevention of vascular disease complications. Current Atherosclerosis Reports. 2017;19(12):56. DOI: https://doi.org/10.1007/s11883-017-0698-2.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gardin C, Ferroni L, Leo S, Tremoli E, Zavan B. Platelet-derived exosomes in atherosclerosis. International Journal of Molecular Sciences. 2022;23(20):12546. DOI: https://doi.org/10.3390/ijms232012546.</mixed-citation><mixed-citation xml:lang="en">Gardin C, Ferroni L, Leo S, Tremoli E, Zavan B. Platelet-derived exosomes in atherosclerosis. International Journal of Molecular Sciences. 2022;23(20):12546. DOI: https://doi.org/10.3390/ijms232012546.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Berger M, Dressel A, Kleber ME, März W, Hellstern P, Marx N, et al. Platelet reactivity and cardiovascular mortality risk in the LURIC study. Journal of Clinical Medicine. 2023;12(5):1913. DOI: https://doi.org/10.3390/jcm12051913.</mixed-citation><mixed-citation xml:lang="en">Berger M, Dressel A, Kleber ME, März W, Hellstern P, Marx N, et al. Platelet reactivity and cardiovascular mortality risk in the LURIC study. Journal of Clinical Medicine. 2023;12(5):1913. DOI: https://doi.org/10.3390/jcm12051913.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Badimon L, Suades R, Arderiu G, Peña E, Chiva-Blanch G, Padró T. Microvesicles in atherosclerosis and angiogenesis: From bench to bedside and reverse. Frontiers in Cardiovascular Medicine. 2017;4:77. DOI: https://doi.org/10.3389/fcvm.2017.00077.</mixed-citation><mixed-citation xml:lang="en">Badimon L, Suades R, Arderiu G, Peña E, Chiva-Blanch G, Padró T. Microvesicles in atherosclerosis and angiogenesis: From bench to bedside and reverse. Frontiers in Cardiovascular Medicine. 2017;4:77. DOI: https://doi.org/10.3389/fcvm.2017.00077.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Muravlev IA, Dobrovolsky AB, Antonova OA, Khaspekova SG, Mazurov AV. Effects of platelets activated by different agonists on fibrin formation and thrombin generation. Platelets. 2023;34(1):2139365. DOI: https://doi.org/10.1080/09537104.2022.2139365.</mixed-citation><mixed-citation xml:lang="en">Muravlev IA, Dobrovolsky AB, Antonova OA, Khaspekova SG, Mazurov AV. Effects of platelets activated by different agonists on fibrin formation and thrombin generation. Platelets. 2023;34(1):2139365. DOI: https://doi.org/10.1080/09537104.2022.2139365.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Esmon CT. The interactions between inflammation and coagulation. British Journal of Haematology. 2005;131(4):417–430. DOI: https://doi.org/10.1111/j.1365-2141.2005.05753.x.</mixed-citation><mixed-citation xml:lang="en">Esmon CT. The interactions between inflammation and coagulation. British Journal of Haematology. 2005;131(4):417–430. DOI: https://doi.org/10.1111/j.1365-2141.2005.05753.x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Visser M, Heitmeier S, Ten Cate H, Spronk HMH. Role of factor XIa and plasma kallikrein in arterial and venous thrombosis. Thrombosis and Haemostasis. 2020;120(6):883–993. DOI: https://doi.org/10.1055/s-0040-1710013.</mixed-citation><mixed-citation xml:lang="en">Visser M, Heitmeier S, Ten Cate H, Spronk HMH. Role of factor XIa and plasma kallikrein in arterial and venous thrombosis. Thrombosis and Haemostasis. 2020;120(6):883–993. DOI: https://doi.org/10.1055/s-0040-1710013.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sprynger M, Rigo F, Moonen M, Aboyans V, Edvardsen T, de Alcantara ML, et al.; EACVI Scientific Documents Committee. Focus on echovascular imaging assessment of arterial disease: Complement to the ESC guidelines (PARTIM 1) in collaboration with the Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal — Cardiovascular Imaging. 2018;19(11):1195–1221. DOI: https://doi.org/10.1093/ehjci/jey103.</mixed-citation><mixed-citation xml:lang="en">Sprynger M, Rigo F, Moonen M, Aboyans V, Edvardsen T, de Alcantara ML, et al.; EACVI Scientific Documents Committee. Focus on echovascular imaging assessment of arterial disease: Complement to the ESC guidelines (PARTIM 1) in collaboration with the Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal — Cardiovascular Imaging. 2018;19(11):1195–1221. DOI: https://doi.org/10.1093/ehjci/jey103.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovascular Diseases. 2007;23(1):75–80. DOI: https://doi.org/10.1159/000097034.</mixed-citation><mixed-citation xml:lang="en">Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovascular Diseases. 2007;23(1):75–80. DOI: https://doi.org/10.1159/000097034.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Atkov OY, Balakhonova TV, Gorokhova SG, Saidova MA, Smolyaninova NG, Aleksandrova-Tebenkova ES, et al. Ultrasound examination of the heart and blood vessels. Moscow: Eksmo; 2015. 456 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="en">Atkov OY, Balakhonova TV, Gorokhova SG, Saidova MA, Smolyaninova NG, Aleksandrova-Tebenkova ES, et al. Ultrasound examination of the heart and blood vessels. Moscow: Eksmo; 2015. 456 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hathout GM, Fink JR, El-Saden SM, Grant EG. Sonographic NASCET index: A new doppler parameter for assessment of internal carotid artery stenosis. American Journal of Neuroradiology. 2005;26(1):68–75. PMID: https://pubmed.ncbi.nlm.nih.gov/15661704.</mixed-citation><mixed-citation xml:lang="en">Hathout GM, Fink JR, El-Saden SM, Grant EG. Sonographic NASCET index: A new doppler parameter for assessment of internal carotid artery stenosis. American Journal of Neuroradiology. 2005;26(1):68–75. PMID: https://pubmed.ncbi.nlm.nih.gov/15661704.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Gerhard-Herman M, Gardin JM, Jaff M, Mohler E, Roman M, Naqvi TZ. Guidelines for noninvasive vascular laboratory testing: A report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. Vascular Medicine. 2006;11(3):183–200. DOI: https://doi.org/10.1177/1358863x06070516.</mixed-citation><mixed-citation xml:lang="en">Gerhard-Herman M, Gardin JM, Jaff M, Mohler E, Roman M, Naqvi TZ. Guidelines for noninvasive vascular laboratory testing: A report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. Vascular Medicine. 2006;11(3):183–200. DOI: https://doi.org/10.1177/1358863x06070516.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fadeeva OA, Panteleev MA, Karamzin SS, Balandina AN, Smirnov IV, Ataullakhanov FI. Thromboplastin immobilized on polystyrene surface exhibits kinetic characteristics close to those for the native protein and activates in vitro blood coagulation similarly to thromboplastin on fibroblasts. Biochemistry (Moscow). 2010;75(6):734–743. DOI: https://doi.org/10.1134/s0006297910060088.</mixed-citation><mixed-citation xml:lang="en">Fadeeva OA, Panteleev MA, Karamzin SS, Balandina AN, Smirnov IV, Ataullakhanov FI. Thromboplastin immobilized on polystyrene surface exhibits kinetic characteristics close to those for the native protein and activates in vitro blood coagulation similarly to thromboplastin on fibroblasts. Biochemistry (Moscow). 2010;75(6):734–743. DOI: https://doi.org/10.1134/s0006297910060088.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Safiullina SI, Feiskhanova LI. The state of thrombotic readiness in clinical practice. Part 1. Kazan: Kazan State Medical University; 2017. 35 p. EDN: https://elibrary.ru/ysxqgs.</mixed-citation><mixed-citation xml:lang="en">Safiullina SI, Feiskhanova LI. The state of thrombotic readiness in clinical practice. Part 1. Kazan: Kazan State Medical University; 2017. 35 p. EDN: https://elibrary.ru/ysxqgs.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lee KW, Blann AD, Lip GY. High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: Relationship to thrombogenesis and endothelial damage/dysfunction. American Journal of Hypertension. 2005;18(1):104–115. DOI: https://doi.org/10.1016/j.amjhyper.2004.09.003.</mixed-citation><mixed-citation xml:lang="en">Lee KW, Blann AD, Lip GY. High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: Relationship to thrombogenesis and endothelial damage/dysfunction. American Journal of Hypertension. 2005;18(1):104–115. DOI: https://doi.org/10.1016/j.amjhyper.2004.09.003.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Yang P, Liu YF, Yang L, Wei Q, Zeng H. Mechanism and clinical significance of the prothrombotic state in patients with essential hypertension. Clinical Cardiology. 2010;33(6):E81–E86. DOI: https://doi.org/10.1002/clc.20719.</mixed-citation><mixed-citation xml:lang="en">Yang P, Liu YF, Yang L, Wei Q, Zeng H. Mechanism and clinical significance of the prothrombotic state in patients with essential hypertension. Clinical Cardiology. 2010;33(6):E81–E86. DOI: https://doi.org/10.1002/clc.20719.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Aboukhater D, Morad B, Nasrallah N, Nasser SA, Sahebkar A, Kobeissy F, et al. Inflammation and hypertension: Underlying mechanisms and emerging understandings. Journal of Cellular Physiology. 2023;238(6):1148–1159. DOI: https://doi.org/10.1002/jcp.31019.</mixed-citation><mixed-citation xml:lang="en">Aboukhater D, Morad B, Nasrallah N, Nasser SA, Sahebkar A, Kobeissy F, et al. Inflammation and hypertension: Underlying mechanisms and emerging understandings. Journal of Cellular Physiology. 2023;238(6):1148–1159. DOI: https://doi.org/10.1002/jcp.31019.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Voskresenskaia ON, Zakharova NB, Ivanov MV. Mechanisms of development of chronic cerebral ischemia in arterial hypertension. S. S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2):68–71. (In Russ.). DOI: https://doi.org/10.17116/jnevro20171172168-71.</mixed-citation><mixed-citation xml:lang="en">Voskresenskaia ON, Zakharova NB, Ivanov MV. Mechanisms of development of chronic cerebral ischemia in arterial hypertension. S. S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2):68–71. (In Russ.). DOI: https://doi.org/10.17116/jnevro20171172168-71.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Gyawali P, Lillicrap TP, Tomari S, Bivard A, Holliday E, Parsons M, et al. Whole blood viscosity is associated with baseline cerebral perfusion in acute ischemic stroke. Neurological Sciences. 2022;43(4):2375–2381. DOI: https://doi.org/10.1007/s10072-021-05666-5.</mixed-citation><mixed-citation xml:lang="en">Gyawali P, Lillicrap TP, Tomari S, Bivard A, Holliday E, Parsons M, et al. Whole blood viscosity is associated with baseline cerebral perfusion in acute ischemic stroke. Neurological Sciences. 2022;43(4):2375–2381. DOI: https://doi.org/10.1007/s10072-021-05666-5.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Wadowski PP, Schörgenhofer C, Rieder T, Ertl S, Pultar J, Serles W, et al. Microvascular rarefaction in patients with cerebrovascular events. Microvascular Research. 2022;140:104300. DOI: https://doi.org/10.1016/j.mvr.2021.104300.</mixed-citation><mixed-citation xml:lang="en">Wadowski PP, Schörgenhofer C, Rieder T, Ertl S, Pultar J, Serles W, et al. Microvascular rarefaction in patients with cerebrovascular events. Microvascular Research. 2022;140:104300. DOI: https://doi.org/10.1016/j.mvr.2021.104300.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Gritsay NN, Mishchenko VP, Pinchuk VA. Hemostasis system in disorders of cerebral circulation. Mezhdunarodnyy nevrologicheskiy zhurnal = International Journal of Neurology. 2006;5(9):53–57. (In Russ.).</mixed-citation><mixed-citation xml:lang="en">Gritsay NN, Mishchenko VP, Pinchuk VA. Hemostasis system in disorders of cerebral circulation. Mezhdunarodnyy nevrologicheskiy zhurnal = International Journal of Neurology. 2006;5(9):53–57. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Barakzie A, Jansen AJG, Ten Cate H, de Maat MPM. Coagulation biomarkers for ischemic stroke. Research and Practice in Thrombosis and Haemostasis. 2023;7(4):100160. DOI: https://doi.org/10.1016/j.rpth.2023.100160.</mixed-citation><mixed-citation xml:lang="en">Barakzie A, Jansen AJG, Ten Cate H, de Maat MPM. Coagulation biomarkers for ischemic stroke. Research and Practice in Thrombosis and Haemostasis. 2023;7(4):100160. DOI: https://doi.org/10.1016/j.rpth.2023.100160.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets. 2005;16(5):269–280. DOI: https://doi.org/10.1080/09537100400020567.</mixed-citation><mixed-citation xml:lang="en">McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets. 2005;16(5):269–280. DOI: https://doi.org/10.1080/09537100400020567.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Noh KC, Choi HY, Woo HG, Chang JY, Heo SH, Chang DI, et al. High-on-aspirin platelet reactivity differs between recurrent ischemic stroke associated with extracranial and intracranial atherosclerosis. Journal of Clinical Neurology. 2022;18(4):421–427. DOI: https://doi.org/10.3988/jcn.2022.18.4.421.</mixed-citation><mixed-citation xml:lang="en">Noh KC, Choi HY, Woo HG, Chang JY, Heo SH, Chang DI, et al. High-on-aspirin platelet reactivity differs between recurrent ischemic stroke associated with extracranial and intracranial atherosclerosis. Journal of Clinical Neurology. 2022;18(4):421–427. DOI: https://doi.org/10.3988/jcn.2022.18.4.421.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. The New England Journal of Medicine. 2017;377(14):1319–1330. DOI: https://doi.org/10.1056/NEJMoa1709118.</mixed-citation><mixed-citation xml:lang="en">Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. The New England Journal of Medicine. 2017;377(14):1319–1330. DOI: https://doi.org/10.1056/NEJMoa1709118.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
